Page 27 - HIVMED_v21_i1.indb
P. 27

Southern African Journal of HIV Medicine
              ISSN: (Online) 2078-6751, (Print) 1608-9693
                                                      Page 1 of 39  Guideline


                Southern African HIV Clinicians Society guidelines for

                        antiretroviral therapy in adults: 2020 update






               Authors:                Table of contents
               Jeremy Nel   1
               Sipho Dlamini   2
               Graeme Meintjes   3     What is new in the 2020 guidelines update? ..............................................................................1
               Rosie Burton   4
                       5
               John M. Black           1.   Preamble .............................................................................................................................1
               Natasha E.C.G. Davies   6
               Eric Hefer              2.     Nucleoside or nucleotide reverse transcriptase inhibitor class of
                     7
               Gary Maartens   8            antiretroviral drugs .............................................................................................................3
               Phetho M. Mangena 9,10
                           11
               Moeketsi T. Mathe       3.   Integrase strand transfer inhibitor class of antiretroviral drugs ..........................................5
                              12
               Mahomed-Yunus Moosa
               Muhangwi B. Mulaudzi    4.   Non-nucleoside reverse transcriptase inhibitor class of antiretroviral drugs .....................6
                             13
               Michelle Moorhouse
                            14
               Jennifer Nash           5.   Protease inhibitor class of antiretroviral drugs ...................................................................8
                       15
               Thandeka C. Nkonyane 16, 17
               Wolfgang Preiser 18,19    6.   Initiation and timing of antiretroviral therapy ....................................................................9
               Mohammed S. Rassool
                             20
               David Stead 21, 22      7.   Baseline investigations ......................................................................................................11
               Helen van der Plas   2
               Cloete van Vuuren 23, 24    8.   Viral load ...........................................................................................................................11
               Willem D.F. Venter
                           25
                                               +
               Joana F. Woods          9.   CD4  count ........................................................................................................................13
                         25
               Affiliations:           10.  Resistance and genotyping ...............................................................................................14
               1 Helen Joseph
               Hospital, Department    11.  Initial antiretroviral therapy regimens for the previously untreated patient ....................16
               of Medicine, University
               of the Witwatersrand,   12.  Management of patients currently receiving first-line therapy ........................................17
               Johannesburg, South Africa
                                       13.  Management of patients starting or currently receiving second-line therapy .................19
               2 Department of Infectious
               Diseases, Faculty of Medicine,   14.  Third-line antiretroviral therapy .......................................................................................21
               University of Cape Town,   15.  Laboratory monitoring of the efficacy and safety of antiretroviral therapy .....................22
               Cape Town, South Africa
                                       16.   Patients who return after stopping antiretroviral therapy ................................................23
               3 Department of Medicine,
               Division of Infectious   17.  Drug–drug interactions .....................................................................................................24
               Diseases and HIV Medicine,
               Groote Schuur Hospital,   18.  Tuberculosis ......................................................................................................................25
               University of Cape Town,
               Cape Town, South Africa  19.  Pregnancy and breastfeeding ...........................................................................................26
               4 Southern African Medical   20.  Liver disease......................................................................................................................28
               Unit, Médecins Sans Frontières
               (MSF), Cape Town, South   21.  Renal disease ....................................................................................................................29
               Africa
                                       22.  Psychiatric disease ............................................................................................................30
               5 Department of Medicine,   23.  Malaria ..............................................................................................................................30
               Division of Infectious
               Diseases, Livingstone Tertiary   24.  Antiretroviral drug-induced liver injury ............................................................................31
               Hospital, Port Elizabeth,
               South Africa            25.  Dyslipidaemia ....................................................................................................................32
               6 Anova Health Institute,   26.  Immune reconstitution inflammatory syndrome ..............................................................33
               Johannesburg ,South Africa
                                       27.  Opportunistic infection prophylaxis ..................................................................................34
                                       28.  Adherence .........................................................................................................................35
               Read online:
                         Scan this QR   29.  Acknowledgments ............................................................................................................36
                         code with your
                         smart phone or   30.  Abbreviations ....................................................................................................................36
                         mobile device
                         to read online.
                                       31.  References ........................................................................................................................37


                                           http://www.sajhivmed.org.za  19  Open Access
   22   23   24   25   26   27   28   29   30   31   32